Estimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spain

Darbà, JosepRamírez, GabrielaGarcía-Rivero, Juan L.Mayoralas, SagrarioPascual, José FranciscoVargas, DiegoBijedic, Adi2017-03-022017-03-022017-021178-6981https://hdl.handle.net/2445/107750The objective of this study was to estimate the economic impact of the introduction of DuoResp® Spiromax®, budesonide/formoterol fixed-dose combination (FDC), focusing on an increase in medication adherence due to an enhancement of the inhalation technique for the treatment of COPD patients in Spain and 5 regions including Andalusia, Catalonia, Galicia, Madrid, and Valencia. ...11 p.application/pdfengcc-by-nc (c) Darbà, Josep et al., 2017http://creativecommons.org/licenses/by-nc/3.0/esAdministració de medicamentsMalalties pulmonars obstructives cròniquesTractament tèrmicEconomia de la salutAdministration of drugsChronic obstructive pulmonary diseasesHeat treatmentMedical economicsEstimating the economic consequences of an increased medication adherence due to a potential improvement in the inhaler technique with Spiromax compared with Turbuhaler in patients with moderate-to-severe chronic obstructive pulmonary disease in Spaininfo:eu-repo/semantics/article6683962017-03-02info:eu-repo/semantics/openAccess28228660